Article

Lipid and Lipoprotein Profiles in Youth With and Without Type 1 Diabetes The SEARCH for Diabetes in Youth Case-Control Study

Department of Epidemiology, Colorado School of Public Health, University of Colorado, Denver, Colorado, USA.
Diabetes care (Impact Factor: 8.57). 12/2008; 32(3):416-20. DOI: 10.2337/dc08-1775
Source: PubMed

ABSTRACT The purpose of this study was to compare the lipid profile and the prevalence of lipid abnormalities in youth with and without type 1 diabetes and explore the role of glycemic control on the hypothesized altered lipid profile in youth with type 1 diabetes.
We conducted a cross-sectional analysis of 512 youth with type 1 diabetes (mean duration 4.22 years) and 188 healthy control subjects aged 10-22 years in Colorado and South Carolina. SEARCH for Diabetes in Youth (SEARCH) participants with type 1 diabetes and healthy control subjects recruited from primary care offices in the same geographic regions were invited to attend a research visit. Fasting lipid profiles were compared between youth with type 1 diabetes (stratified according to categories of optimal [A1C <7.5%] and suboptimal [A1C >or=7.5%] glycemic control) and healthy nondiabetic youth, using multiple linear and logistic regression.
Youth with type 1 diabetes and optimal A1C had lipid concentrations that were similar (total cholesterol, LDL cholesterol, and LDL particle size) or even less atherogenic (HDL cholesterol, non-HDL cholesterol, triglyceride, and triglyceride-to-HDL cholesterol ratio) than those observed in nondiabetic youth, whereas youth with suboptimal glycemic control had elevated standard lipid levels (total cholesterol, LDL cholesterol, and non-HDL cholesterol). Youth with type 1 diabetes also had significantly elevated apolipoprotein B levels and more small, dense LDL particles than nondiabetic youth, regardless of glycemic control.
Youth with type 1 diabetes have abnormal lipid levels and atherogenic changes in lipoprotein composition, even after a relatively short disease duration. As in adults, glycemic control is an important mediator of these abnormalities.

Download full-text

Full-text

Available from: Dana Dabelea, Sep 02, 2015
1 Follower
 · 
89 Views
 · 
35 Downloads
  • Source
    • "This result is in concordance with Muchacka-Bianga et al. (2006) and Kantoosh et al. (2002) who found that lipid disorders in children with T1DM may be present regardless of their metabolic con- trol. 14,22 On the contrary, Teles and Forne´s (2012) and Guy et al. (2009) found that poorer (inadequate) glycemic control is related to higher serum lipids levels.. 19,21 Ladeia et al. (2006) and Krantz et al. (2004) found significant correlations between glycemic control and lipids. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is associated with a high risk of cardiovascular disease (CVD). The classic “diabetic dyslipidemia” is mostly described as hypertriglyceridemia and low levels of HDL-C. Elevated LDL-C is an established risk factor for CVD.
    The Gazette of the Egyptian Paediatric Association 04/2015; 27(2). DOI:10.1016/j.epag.2015.03.001
  • Source
    • "M. Geoffrion et al. 2007; Guy et al. 2009) although this is not as exaggerated as that which is seen in the diabetic Apoe À/À mice. The hypercholesterolemia that occurs in the Apoe À/À mice following STZ administration has been considered a shortcoming in this mouse model of human diabetic cardiovascular disease (Renard and Van Obberghen 2006; Hsueh et al. 2007; Kanter et al. 2007; Ramasamy and Goldberg 2010) and, in our case, may mask any macrovascular protective effects that are due to reducing dicarbonyl stress through overexpression of GLO1. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The reactive dicarbonyls, glyoxal and methylglyoxal (MG), increase in diabetes and may participate in the development of diabetic complications. Glyoxal and MG are detoxified by the sequential activities of glyoxalase 1 (GLO1) and glyoxalase 2. To determine the contribution of these dicarbonyls to the etiology of complications, we have genetically manipulated GLO1 levels in apolipoprotein E-null (Apoe(-/-)) mice. Male Apoe(-/-) mice, hemizygous for a human GLO1 transgene (GLO1TGApoe(-/-) mice) or male nontransgenic Apoe(-/-) litter mates were injected with streptozotocin or vehicle and 6 or 20 weeks later, aortic atherosclerosis was quantified. The GLO1 transgene lessened streptozotocin (STZ)-induced increases in immunoreactive hydroimidazolone (MG-H1). Compared to nondiabetic mice, STZ-treated GLO1TGApoe(-/-) and Apoe(-/-) mice had increased serum cholesterol and triglycerides and increased atherosclerosis at both times after diabetes induction. While the increased GLO1 activity in the GLO1TGApoe(-/-) mice failed to protect against diabetic atherosclerosis, it lessened glomerular mesangial expansion, prevented albuminuria and lowered renal levels of dicarbonyls and protein glycation adducts. Aortic atherosclerosis was also quantified in 22-week-old, male normoglycemic Glo1 knockdown mice on an Apoe(-/-) background (Glo1KDApoe(-/-) mice), an age at which Glo1KD mice exhibit albuminuria and renal pathology similar to that of diabetic mice. In spite of ~75% decrease in GLO1 activity and increased aortic MG-H1, the Glo1KDApoe(-/-) mice did not show increased atherosclerosis compared to age-matched Apoe(-/-) mice. Thus, manipulation of GLO1 activity does not affect the development of early aortic atherosclerosis in Apoe(-/-) mice but can dictate the onset of kidney disease independently of blood glucose levels.
    06/2014; 2(6). DOI:10.14814/phy2.12043
  • Source
    • "The diabetic phenotype is associated with elevated blood glucose and lipid concentrations [43]. Circulating levels of FFA can impact cellular signaling and have the potential to affect Ca2+ mobilization. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The effects of cytokine and fatty acid treatment on signal transduction in dermal fibroblasts from type 1 diabetics and matched controls were compared. Chronic exposure to TNF, accentuated Ca(2+) mobilization in response to bradykinin (BK) in cells from both controls and diabetics; responses were three-fold greater in cells from diabetics than in controls. Similarly, with chronic exposure to IL-1β, BK-induced Ca(2+) mobilization was accentuated in cells from type 1 diabetics compared to the controls. Pretreatment with the protein synthesis inhibitor cycloheximide or the protein kinase C inhibitor calphostin C prior to the addition of TNF completely abrogated the TNF-induced increment in peak bradykinin response. Ca(2+) transients induced by depleting endoplasmic reticulum (ER) Ca(2+) with thapsigargin were also greater in TNF treated fibroblasts than in untreated cells, with greater increases in cells from diabetics. Exposing fibroblasts for 48 hours to 2 mM oleate also increased both the peak bradykinin response and the TNF-induced increment in peak response, which were significantly greater in diabetics than controls. These data indicate that cells from diabetic patients acquire elevated ER Ca(2+) stores in response to both cytokines and free fatty acids,and thus exhibit greater sensitivity to environmental inflammatory stimuli and elevated lipids.
    PLoS ONE 01/2014; 9(1):e87068. DOI:10.1371/journal.pone.0087068 · 3.23 Impact Factor
Show more